Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.48 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | PTGES | O14684 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575045 | 0.84 | SERPINE1 (0.47) | MEN1KMT2ALMNA | |
| SCHEMBL3583289 | 0.79 | MEN1 (0.55) | MEN1KMT2ASRD5A2LMNA | |
| SCHEMBL3579626 | 0.78 | MEN1 (0.53) | MEN1KMT2ASRD5A2LPAR1LPAR5 | |
| SCHEMBL3576772 | 0.77 | MLYCD (0.48) | MEN1KMT2ALMNAATM | |
| SCHEMBL3576443 | 0.77 | MLYCD (0.48) | MEN1KMT2ALMNAATM | |
| SCHEMBL8739023 | 0.75 | MEN1 (0.76) | MEN1KMT2AATM | |
| SCHEMBL9079600 | 0.73 | LPAR1 (0.56) | LPAR1LPAR5PTGES | |
| SCHEMBL3641494 | 0.72 | NPC1 (0.55) | MEN1KMT2ALMNA | |
| SCHEMBL9080884 | 0.72 | LPAR1 (0.64) | KMT2ASRD5A2LPAR1LPAR5PTGES | |
| SCHEMBL19583686 | 0.72 | HTT (0.51) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | AADAT, AAAS, AADAC | MEN1 1293/4885KMT2A 341/4885SRD5A2 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.